Investors Sue Aquestive Therapeutics Over Alleged NDA Disclosures in Anaphylm Case

A recent lawsuit has been filed against Aquestive Therapeutics, Inc., by investors claiming that the company failed to adequately disclose significant deficiencies related to the Anaphylm NDA. This legal action has arisen against the backdrop of considerable financial losses experienced by shareholders following alarming FDA disclosures about the drug’s approval process.

According to reports from SueWallSt, a firm specializing in investor litigation, the stock price of Aquestive Therapeutics nosedived from $6.21 to $3.91 on January 9, 2026—translating to an approximate 37% drop in one day. This drastic decline prompted concerns among investors as the FDA flagged deficiencies in the Anaphylm NDA. The timing of this crisis underscores the essence of the lawsuit, as investors seek to reclaim their losses sustained during the period from June 16, 2025, to January 8, 2026.

Allegations of Inadequate Risk Disclosures

In the lawsuit, the plaintiffs assert that the disclosures made by Aquestive were insufficient and primarily constituted general risk warnings typical in the pharmaceutical industry. They argue the company failed to explicitly communicate known obstacles that the Anaphylm NDA faced, particularly concerning human factor studies that the FDA subsequently deemed deficient.

Throughout the litigation timeframe, Aquestive reiterated to investors that the Anaphylm NDA review was on track and that their conversations with the FDA were simply routine. This declaration was made despite existing data indicating regulatory complications that could affect the approval process.

Legal expert Joseph E. Levi, who represents the investors, criticized the reliance on broad risk factor language. He maintains that when specific data reveals identifiable issues impacting product approval, merely stating that the FDA may not approve their products is inadequate. He emphasizes that investors deserved transparency regarding any significant findings from studies that could influence the Anaphylm timeline.

The Impact on Investors

As the case unfolds, numerous investors are left grappling with the repercussions of the sharp stock decline. Many could potentially qualify for free case evaluations to determine the viability of their claims for compensation resulting from the alleged misrepresentations by the company. With a lead plaintiff deadline looming on May 4, 2026, there is a pressing need for affected investors to take timely action.

Levi Korsinsky, LLP, recognized as a premier securities litigation firm, is handling this case and representing affected shareholders. The firm has a track record of successful recoveries in numerous investor disputes, highlighting their capability to pursue justice on behalf of those harmed by corporate mismanagement.

Conclusion

The unfolding situation surrounding Aquestive Therapeutics serves as a significant reminder of the persistent risks that investors face within the pharmaceutical industry. As this lawsuit progresses, stakeholders will be keenly watching how the firm addresses the alleged deficiencies and whether the upcoming findings will favor the disgruntled investors. In a landscape fraught with uncertainty, the quest for transparent risk disclosures remains a fundamental aspect of corporate accountability and investor protection.